Be Biopharma IPO

Be Biopharma (“Be Bio”) is pioneering Engineered B Cell Medicines (BeCM) to dramatically improve patients’ lives who are living with cancer, rare diseases and other serious conditions. The company's medicines address major hurdles of cell and gene therapies, and are durable, re-disable, and can be administered without toxic conditioning, thereby enabling healthcare sectors and patients to treat diseases like cancer, autoimmune conditions, and an enzyme deficiency. Be Bio is developing a proprietary class of engineered B cells as medicines that unleash the potential of cell therapies in applications beyond cytotoxicity. Be Bio was founded in October 2020 by Longwood Fund and B cell engineering pioneers David Rawlings, M.D., and Richard James, Ph.D. from Seattle Children’s Research Institute.

Register for Details

For more details on financing and valuation for Be Biopharma, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Learn more about Be Biopharma

Forge green plus iconForge green minus icon

What is Be Biopharma's IPO price?

The IPO price for Be Biopharma will be known only if it becomes public. However, you may access the "Price At Last Round" and the "Implied EV" for publicly traded comparable companies with Forge Data.
Forge green plus iconForge green minus icon

Can you invest in Be Biopharma?

Be Biopharma is a privately held company and is not publicly traded on NYSE or NASDAQ in the U.S. To buy pre-IPO shares of a private company, you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.

Forge green plus iconForge green minus icon

Can you sell Be Biopharma share pre-IPO?

If you own Be Biopharma pre-IPO shares and are considering selling, you can find what your shares could be worth on Forge’s secondary marketplace.

Our Private Market Specialists are available to answer any questions you might have and can help connect you with a buyer from our network of 125,000 accredited investors and institutions. You can also learn more about how to sell your private shares before getting started.

Forge green plus iconForge green minus icon

Is Be Biopharma a publicly traded company?

Be Biopharma is a private company and not publicly traded.

If you are interested in buying or selling private company shares, you can register with Forge today for free to explore your options. Registering gives you access to one of our Private Market Specialists who can guide you through the process of buying or selling. Learn more about how Forge might help you buy pre-IPO shares or sell pre-IPO shares.

Forge green plus iconForge green minus icon

What is Be Biopharma's funding to date?

Be Biopharma has raised $182.1MM to date.
Forge green plus iconForge green minus icon

When was Be Biopharma founded?

Be Biopharma was founded in 2020.

Who are Be Biopharma's major investors?

Atlas Venture
Ra Capital Management
Longwood Fund
Alta Partners
Takeda Ventures
Arch Venture Partners
Bristol Myers Squibb

Be Biopharma Funding Rounds and Last Known Valuation

Date Funding Round Funding Raised Price per Share Last Known Valuation
4/14/2022 Series B $118MM raised $XXX.XX $XXX.XX
10/22/2020 Series A $64.1MM raised $XXX.XX $XXX.XX
Based on primary financings
Powered by Forge Data
Updated on: Nov 15, 2023

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.